RENOVOGEM Trademark

Trademark Overview

On Friday, March 6, 2020, a trademark application was filed for RENOVOGEM with the United States Patent and Trademark Office. The USPTO has given the RENOVOGEM trademark a serial number of 88824633. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, September 18, 2023. This trademark is owned by RenovoRx, Inc.. The RENOVOGEM trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical products for the prevention and treatment of cancer
renovogem

General Information

Serial Number88824633
Word MarkRENOVOGEM
Filing DateFriday, March 6, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, September 18, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 23, 2020

Trademark Statements

Goods and ServicesPharmaceutical products for the prevention and treatment of cancer

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, March 12, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameRenovoRx, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressLos Altos, CA 94022
Party NameRenovoRx, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
Addresslos altos, CA 94022

Trademark Events

Event DateEvent Description
Monday, September 18, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, September 18, 2023ABANDONMENT - NO USE STATEMENT FILED
Tuesday, March 7, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, March 6, 2023SOU EXTENSION 5 GRANTED
Friday, February 17, 2023SOU EXTENSION 5 FILED
Friday, March 3, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, February 17, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, August 3, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, August 1, 2022SOU EXTENSION 4 GRANTED
Monday, August 1, 2022SOU EXTENSION 4 FILED
Monday, August 1, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, April 5, 2022WITHDRAWAL OF ATTORNEY GRANTED
Tuesday, April 5, 2022TEAS WITHDRAWAL OF ATTORNEY RECEIVED
Tuesday, April 5, 2022APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, April 5, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, April 5, 2022TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, February 1, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Saturday, January 29, 2022SOU EXTENSION 3 GRANTED
Saturday, January 29, 2022SOU EXTENSION 3 FILED
Saturday, January 29, 2022SOU TEAS EXTENSION RECEIVED
Thursday, August 5, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, August 3, 2021SOU EXTENSION 2 GRANTED
Tuesday, August 3, 2021SOU EXTENSION 2 FILED
Tuesday, August 3, 2021SOU TEAS EXTENSION RECEIVED
Friday, February 19, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, February 17, 2021SOU EXTENSION 1 GRANTED
Wednesday, February 17, 2021SOU EXTENSION 1 FILED
Wednesday, February 17, 2021SOU TEAS EXTENSION RECEIVED
Tuesday, August 18, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, June 23, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 23, 2020PUBLISHED FOR OPPOSITION
Wednesday, June 3, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, May 15, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, May 12, 2020ASSIGNED TO EXAMINER
Thursday, March 12, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, March 10, 2020NEW APPLICATION ENTERED

Related Keywords

renovogem cancer treatment prevention products pharmaceutical